Medicine guide
Infergen
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Interferon alfacon-1
- Made by
- Astellas Pharma Europe B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of patients of 18 years and older with chronic hepatitis and serum markers for hepatitis C virus (HCV) infection e.g. those who have elevated serum transaminase levels without decompensated liver disease and who are positive for serum HCV-RNA (see section 4.4). Consideration should be given to current official guidance on the appropriate use of interferons for the treatment of patients with chronic hepatitis C.Interferon alfacon-1 should be given alone mainly in case of intolerance or contraindication to ribavirin.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Astellas Pharma Europe B.V. |
|---|---|
| Active substance | Interferon alfacon-1 |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L03AB09 · Cancer treatments and immune-system medicines |
| Authorised on | 1999-02-01 |
| Last updated by the regulator | 2006-06-01 |
| EMA product number | EMEA/H/C/000186 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).